Fairvalue-Calculator Fairvalue-Calculator
EN DE

Jiangsu Apon Medical Technology Co (300753) Fair Value & Analysis

Healthcare · CN · Market cap 2.6B CNY

Price¥20.37
Fair Value¥23.83
Upside+17.0%
Quality93/100
Evidence: Low Range ¥17.87 – ¥29.79

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Jiangsu Apon Medical Technology Co (300753) currently trades at ¥20.37, while our model-based Fair Value estimate is ¥23.83 — implying the stock looks roughly 17.0% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Jiangsu Apon Medical Technology Co., Ltd. engages in the research and development, production, and sale of medical devices in China. The company's principal products include microcomputer injection pumps, disposable injection pumps, wireless analgesia management systems, and pulse oximeters, as well as medical devices, such as sensors in the field of pain management and nasal care sprayers. Jiangsu Apon Medical Technology Co., Ltd. was founded in 2001 and is headquartered in Nantong, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Jiangsu Apon Medical Technology Co (300753) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥23.83 versus a price of ¥20.37 — about +17% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 300753?
Our 21-model fair value for Jiangsu Apon Medical Technology Co is ¥23.83 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥20.37.
What is the quality score of 300753?
Jiangsu Apon Medical Technology Co has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.